Growing out of the old self: management itself says the company has quietly become a different business, and the numbers
The model's full reasoning — Q4 2021 call → NOWe need answer only YES or NO. Need analyze transcript. Need determine if management conveys both halves. Let's examine transcript. Harrow Health Q4 2021. CEO Mark Baum. Need see if management describes company as crossed into different kind of business, change already real, and reported results/perception lag change. Key excerpts: "our actions in 2021 were intensely focused on positioning Harrow Health to fulfill its vision of becoming a leading U.S. eye care company. For us, to execute on that vision, we are: one, focusing on ophthalmic surgical, chronic and acute care prescription pharmaceuticals; two, serving institutional customers... three, continuing to add high-value FDA-approved products to our portfolio." "In 2022, we are focused on building the infrastructure to support the significant growth that we anticipate over the next few years, beginning this year, not only from recent acquisitions of drug candidates like AMP-100 and MAQ-100, if they're approved by the FDA, but also from internally developed formulations that we expect to launch commercially over the next 18 months or so." "Also, we continue to be on the hunt for additional M&A opportunities... In order to support this growth, we are expanding our existing commercial infrastructure... We expect our team to be further expanded during 2022 as we prepare for the approval and launch of AMP-100 and the relaunch of IOPIDINE, MAXITROL and MOXEZA..." "We are also in the process of establishing our own internal analytical lab..." "This year is already shaping up to be a breakout year for Harrow. We continue to see strong daily revenues to this day. As we previously announced, October 16 of this year is our PDUFA date for AMP-100. And if approved, we intend to be ready a few months thereafter to launch AMP-100 into a market in which we have commercial credibility. That would be the U.S. ophthalmic surgical or procedure market. In addition, we expect to see value creation events from our noncontrolling equity positions in companies that were originally founded as Harrow Health subsidiaries before being deconsolidated." Then Q&A. Brooks asks about COVID. Mark says not material. Brooks: "You seem to be fairly optimistic... about FDA response on AMP-100... ability to get through FDA?" Mark: product patented, market, existing presence.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
CALX · Q1 2023 → YESThe question is whether management conveys that the company today is running on a different basis than what its reported results and reputation were built on. Both parts: a change of basis already rea...YES The transcript shows management describing the company as now operating on a fundamentally different basis—selling into a new market of broadband service providers building consolidated networks, shifting from a legacy cyclical model to sequential revenue through platforms, clouds, and managed services—while treating this as an accomplished reality today, not a future plan. They emphasize numbers like 988 BSP deployments, 865 cloud customers, and 334 managed services customers, along with three years of over 25% growth, as evidence of this new foundation already in place.
SANG · Q2 2024 → YESThe question is whether management conveys that the company today is running on a different basis than the one its reported results and reputation were built on. Both parts: a real change of basis alr...
WD · Q2 2022 → YESThe question is whether management conveys that the company today is running on a different basis than the company its reported results and reputation were built on. Specifically, two parts: a change ...